Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the long-term safety and tolerability of pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease exposed to open-label pimavanserin for up to 52 weeks.

Official Title
-----------------
A 52-Week Open-label Extension Study of Pimavanserin in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Conditions
-----------------
Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Intervention / Treatment
-----------------
* Drug: Pimavanserin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject satisfied all entry criteria for the antecedent pimavanserin study Subject completed the antecedent study; or was participating in a pimavanserin study that the Sponsor ended early Has a designated study partner/caregiver who meets the following requirements: In the Investigator's opinion, is in contact with the subject frequently enough to accurately report on the subject's symptoms and whether or not the subject is taking the study drug In the Investigator's opinion, is considered reliable in providing support to the subject to help ensure compliance with study treatment, study visits, and protocol procedures Is fluent in the local language in which study assessments will be administered Agrees to participate in study assessments, has the capacity to provide informed consent, and provides written consent to participate in the study Subject is willing and able to provide informed consent. If the subject is female, she must not be pregnant or breastfeeding. She must also be of non-childbearing potential (defined as either surgically sterilized or at least 1 year postmenopausal) or must agree to use a clinically acceptable method of contraception or be abstinent during the study and 1 month following completion of the study. Exclusion Criteria: Subject is judged by the Investigator or the Medical Monitor to be inappropriate for the study, due to AEs, medical condition, or noncompliance with investigational product or study procedures in the antecedent study, or is judged to be a danger to self or others Is in hospice, is receiving end-of-life palliative care, or has become bedridden Has any of the following ECG results at the EOT/ET visit of the antecedent study: a. If the subject is not on citalopram, escitalopram, or venlafaxine: i. QTcF >450 ms, if QRS duration <120 ms ii. QTcF >470 ms, if QRS duration ≥120 ms b. If the subject is on citalopram, escitalopram, or venlafaxine: i. QTcF >425 ms, if QRS duration <120 ms ii. QTcF >450 ms, if QRS duration ≥120 ms Has a heart rate <50 beats per minute. If bradycardia is secondary to iatrogenic or treatable causes and these causes are treated, a heart rate assessment can be repeated at the EOT/ET visit of the antecedent study. Has clinically significant laboratory abnormalities in the antecedent study that, in the judgment of the Investigator or Medical Monitor, would either: jeopardize the safe participation of the subject in the study; OR would interfere with the conduct or interpretation of safety or efficacy evaluations in the study Is suicidal at Visit 1 (Baseline) Has developed a medical condition that in the judgment of the Investigator, would increase the risk associated with taking study medication or significantly interfere with the conduct or interpretation of the study Requires treatment with a medication or other substance that is prohibited by the protocol Has a significant sensitivity or allergic reaction to pimavanserin or its excipients Is an employee of ACADIA, or has a family member who is an employee of ACADIA Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically, if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria). -

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Drug - pimavanserin<br>Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response. | Drug: Pimavanserin<br>* • Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| • Treatment-emergent adverse events (TEAEs) |  | Treatment period and Follow-up period: 56 weeks |